Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eiger Biopharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
EIGR
Nasdaq
8731
https://www.eigerbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eiger Biopharmaceuticals Inc
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
- Jan 18th, 2024 10:49 pm
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
- Jan 4th, 2024 1:00 pm
Eiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock Purchase
- Dec 4th, 2023 1:02 pm
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 9th, 2023 9:05 pm
UPDATE 1-Eiger to discontinue hepatitis drug study over safety concerns
- Sep 12th, 2023 8:27 pm
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta
- Sep 12th, 2023 8:05 pm
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 8:05 pm
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 14th, 2023 8:05 pm
RigiTech enables drone delivery — without a landing or takeoff
- Jul 6th, 2023 7:30 pm
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO
- Jun 29th, 2023 12:00 pm
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow
- Jun 28th, 2023 8:05 pm
Eiger BioPharmaceuticals Slides As Insider Purchases Lose Another US$81k
- Jun 27th, 2023 12:08 pm
Investors Holding Back On Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
- May 31st, 2023 11:25 am
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
- May 11th, 2023 8:00 pm
Eiger BioPharmaceuticals (NASDAQ:EIGR) adds US$9.4m to market cap in the past 7 days, though investors from five years ago are still down 88%
- May 4th, 2023 10:49 am
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- May 3rd, 2023 8:05 pm
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments
- Apr 13th, 2023 12:00 pm
Some Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Just Made A Major Cut To Next Year's Estimates
- Mar 31st, 2023 10:17 am
Scroll